

# bio-dundee

CELEBRATING 20 YEARS

IN ASSOCIATION WITH



AMICULUM®

Medtronic

## CONFERENCE PROGRAMME

Programme brought to you by

**\*symbiosis**  
Pharmaceutical Services

SPONSORED BY



# Welcome


---

## AMICULUM

AMICULUM is delighted to support the 20th BioDundee International Conference, where thought leaders and organisations come together from across the life sciences sector to share knowledge and expertise. As an independent global healthcare communications and consultancy business, we value the wealth of life sciences talent that Dundee offers and the collaborative environment fostered by BioDundee. Like BioDundee, AMICULUM is celebrating its 20th birthday this year and we are delighted to share that anniversary with friends and colleagues in Scotland. AMICULUM has grown from a self-funded start-up into a global team of over 300 healthcare professionals who work with global pharmaceutical companies in some of the most exciting areas of medicine. We have colleagues across multiple international locations, including a multidisciplinary team based on the campus of the University of Dundee. We're excited to have the opportunity to support this important conference and look forward to the varied line-up of speakers and informative sessions.

## Medtronic

Medtronic is incredibly proud to be continuing as a main sponsor of BioDundee in its anniversary year. Throughout our 72 year history, innovation in technology and solutions has been central to our Mission to alleviate pain, restore health, and extend life across the world. BioDundee leads in building world-class partnerships between public, private, academic and third sector organisations, partnerships which Medtronic is passionate to collaborate in so we can take healthcare further, together. For Scotland, as indeed the rest of the world, innovation in life sciences is central to the improvement of health and wellbeing, as well as being integral to our economy, and we are delighted to see that this forms the theme for this year's conference. We look forward to the diverse sessions on the programme and are delighted that this year's conference will be accessible to even more people as a free virtual event.



# Conference Itinerary

---

- 09:00** Welcome and Introductions
- 09:20** Session 1 - The UK Landscape for Life Sciences and Healthcare: Funding and Legislation
- 10:00** Comfort Break - Networking and Exhibition
- 10:20** Session 2 - Driving Health Technologies in the New Environment
- 11:00** Comfort Break - Networking and Exhibition
- 11:20** Session 3 - The Pharmaceutical Supply Chain
- 12:00** Lunch - Networking and Exhibition
- 13:00** Session 4 - Animal Health, Agri-tech and Aquaculture (AAA): Strengths and Opportunities in Scotland
- 13:40** Comfort Break - Networking and Exhibition
- 14:00** Session 5 - 20 Years On: Reflecting and Looking to the Future
- 14:40** Comfort Break - Networking and Exhibition
- 15:00** Session 6 - What do the next 20 years hold for the Life Sciences and Healthcare Sectors?
- 15:40** Closing Address
- 16:00** Networking and Exhibition
- 16:30** Virtual Conference Closes

sponsored by



sponsored by



sponsored by



sponsored by



# Session 1: The UK Landscape for Life Sciences and Healthcare: Funding and Legislation

09:20 - 10:00

SPONSORED BY:  **mha**  
HENDERSON LOGGIE



## Rod Mathers, Corporate Finance Partner, MHA Henderson Loggie (Chair)

Rod Mathers is Partner and Head of Corporate Finance at MHA Henderson Loggie. He has extensive experience of advising business owners who are either looking to exit, grow through acquisition or raise finance. Rod has a particular interest in the Life Science sector as head of the sector group at MHA Henderson Loggie and a former Finance Director of a Life Sciences manufacturing business.



## Professor Andrew Hopkins, CEO, Exscientia

Andrew Hopkins is the founder and CEO of the global pharma-tech company, Exscientia, with offices in Oxford, Miami and Osaka. Exscientia uses artificial intelligence (AI) to efficiently discover new drugs and innovative medicines to improve our abilities to discover new medicines. Dr Hopkins's work and research methods are all focused on accelerating the time between the start of an idea to a viable new drug candidate for

patients. At Exscientia, Dr Hopkins has overseen the discovery of the world's first precision engineered drugs generated by AI to enter phase 1 human clinical trials.

Prior to founding Exscientia, Dr Hopkins was the SULSA Research Professor of Translational Biology and the Chair of Medicinal Informatics at the University of Dundee. Before becoming an academic, he held various research leadership positions at Pfizer for 10 years. Hopkins holds a DPhil from the University of Oxford in Molecular Biophysics. He has been awarded Fellowships from several national academies in the UK.

He lives in Oxford, UK, with his wife and daughter.

“  
**Hopkins holds a DPhil from the University of Oxford in Molecular Biophysics.**



## Dr Deborah O'Neil, Chief Executive Officer, NovaBiotics Ltd

A biotechnology entrepreneur and immunologist by training, Deborah has over two decades of experience in anti-infective drug discovery research and development. Deborah studied at University College London and then worked in postdoctoral

positions in internationally acclaimed laboratories in San Diego and Ghent before moving to Aberdeen (to the Rowett Research Institute, now part of the University of Aberdeen) where she founded NovaBiotics in 2004. The business has since become a leading global biotechnology business, developing a portfolio of first-in-class anti-infective therapies addressing the urgent, unmet need for safe and effective antimicrobials including Nylexa for COVID-19. NovaBiotics is on the front line of the fight against antimicrobial resistance (AMR).

Deborah is a Board member of the UK's BioIndustry Association, a Director and founding member of the BEAM Alliance (Biotech of Europe innovating in Anti-Microbial Resistance), was a member of the Scottish Life Sciences Industry Leadership Group and sit on the

Boards of the Scottish Life Sciences Association and Opportunity North East Life Science/BioAberdeen. Deborah serves as Chairperson of the UK's Medicines Discovery Catapult-Cystic fibrosis (CF) Trust's working group on antimicrobials in CF and sits on the UK BioIndustry Association's working group on AMR. Elected as a Fellow of the Royal Society of Edinburgh in 2018 and a Fellow of the Royal Society of Medicine. Named as one of the 20 women leaders in European biotech in 2019, one of the 30 top female leaders in UK Healthcare in 2018 one of the 15 leading women European biotech in 2017. In 2020, Deborah was made OBE in the Queen's Birthday Honours list, for services to biotechnology, industry and charity.

# Session 1: The UK Landscape for Life Sciences and Healthcare: Funding and Legislation

09:20 - 10:00

SPONSORED BY:



## Dr Andrew McNeill, Managing Partner, Eos Advisory

Andrew McNeill has over 15 years' experience in leading early stage venture capital backed medical device and biotech companies. Over this period, he has focused on commercialising innovative new technologies based upon strong intellectual property. He joined Eos in 2017 and is responsible for managing new investment opportunities and transactions.

“  
**He is responsible for managing new investment opportunities and transactions.**

Prior to this he was part of the founding team at Ambicare Health, a medical device company in the oncology space and took several technologies from lab through to market. Subsequent to that he joined Glasgow based biotechnology company Fixed Phage as CEO. He is currently Investor Director for a number of Eos portfolio Companies. Andrew holds a PhD in Molecular Physics from Leeds University.



## Dr Samantha Atkinson, Interim Chief Quality & Access Officer, Medicines and Healthcare products Regulatory Agency (MHRA)

Sam oversees a large portfolio that is designed to ensure the quality and access of products to the UK market - this includes scientific advice, clinical trials/clinical investigations, licensing assessment, marketing authorisations and device registrations, inspections, enforcement and standard setting through for example the British Pharmacopoeia and Target Product Profiles.

Sam was appointed to Interim Chief Quality & Access Officer in September 2020. Prior to this Sam held several roles at the MHRA including Director of Inspection, Enforcement & Standards (IE&S), Director of Business

Transformation, Deputy Director for IE&S, and Scientific Director for the British Pharmacopoeia (BP) and Laboratory Services. Sam also worked in the Inspectorate for several years, performing inspections, nationally and overseas. Prior to joining the MHRA, Sam worked in industry for a number of years.

“  
**Prior to joining the MHRA, Sam worked in industry for a number of years.**

Sam studied chemistry at Reading University, completed an MBA at Warwick University and has also completed the Civil Service Major Project Leadership Academy. Sam is a member of the Royal Society of Chemistry and a Visiting Research Fellow at Reading University, playing an active role promoting public sector opportunities to science graduates.

# Session 2: Driving Health Technologies in the New Environment

10:20 - 11:00

SPONSORED BY: 



**Peter Ellingworth, Chief Executive, ABHI (CHAIR)**

Peter leads the Association of British HealthTech Industries (ABHI), the UK's leading HealthTech trade association, representing 300 companies in MedTech, diagnostics and digital health. Peter currently sits on the Secretary of State led Life Sciences Council, and the sector specific Health Technology Partnership which supports it. He is also a member of the Life Sciences Scotland Industry Leadership Group. In 2018 he was appointed to the advisory board of Healthcare UK, the government agency responsible for promoting the UK healthcare sector to overseas markets. Peter also sits on the advisory council of EXCITE International, a global collaborative seeking to accelerate access to health technologies. Peter is a GlobalScot - a worldwide network of business contacts who are experts in their field, and driven to help Scottish companies develop, expand and thrive in a competitive international market.



**Mark Cook, Director of Government Affairs, Medtronic**

Mark has spent 30 years in roles within the health sector including biologicals/pharmaceuticals, medical technology and consultancy before joining Medtronic in 2008.

Currently responsible for determining the direction of Medtronic in areas such as strategy, government relations policy including the implications of BREXIT for the UK and individually within the devolved nations, as well as issues surrounding regulation and trade.



**Professor Emily Jefferson, Director Health Informatics Centre (HIC), University of Dundee**

In addition, Mark represents Medtronic in industry trade bodies including ABHI (Chairs ABHI Scotland), MedTech Europe, ADVAMED and has published on healthcare resource utilisation in areas such as diabetes, hypertension and heart failure.

In February 2018 Mark joined the Life Sciences Industrial Leadership Group in Scotland and currently serves as its Vice Chair and head of governance, he also continues to support decision making for non-medicine technologies through membership of the Scottish Health Technology Group.

In Tayside, Mark has led on the partnership between University of Dundee, NHS Tayside & Medtronic which has led to the creation of Dundee Institute Of Healthcare Simulation and inclusion of MedTech requests within the Tay Cities bids.

Professor Emily Jefferson is chair of Health Data Science and Director of the Health Informatics Centre (HIC) at the University of Dundee. Emily leads a team of c.60 providing services to over 700 different research projects providing expertise in health informatics, data science, data management, governance, and machine learning. She is responsible for an ISO27001 certified infrastructure of ~300 servers and a Scottish Government accredited Safe Haven.

Emily's main research interest is in innovative methods for the provision of sensitive linked

[Continued →](#)

# Session 2: Driving Health Technologies in the New Environment

10:20 - 11:00

SPONSORED BY: 

data which meets both data governance requirements and those of the research community.

Emily is Co-PI on CO-CONNECT, a £4M project building a UK wide federated infrastructure for COVID data in partnership with HDR and supporting the National core studies programme. She is also leading a £3.8M programme grant (PICTURES), in collaboration with the University of Edinburgh, Abertay University and National Services Scotland. This programme is enabling safe and secure research access to linked, routinely collected radiological images stored within the Scottish National PACS system. She is also leading the UK-wide imaging interoperability strategy on behalf of Health Data Research (HDR) UK. Emily leads the informatics work stream of a large Horizon 2020 EU project (ENSAT-HT) using machine learning to stratify individuals with different types of hypertension from multi-omics markers. Emily also works on a range of other HDR UK projects and other research projects.



**Dr Debbie Wake, CEO and cofounder MyWay Digital Health, NHS Diabetes Consultant, Clinical Reader University of Edinburgh**

Dr Debbie Wake is CEO and co-founder of MyWay Digital Health ([www.mwdh.co.uk](http://www.mwdh.co.uk)) (MWDH) (University of Dundee spin out company) in 2017. MWDHs vision is to improve the lives of people with diabetes globally through affordable data-driven solutions. Their flagship product; My Diabetes My Way (MDMW), is multi-award winning, improves

health outcomes and saves costs (5:1 ROI). MDMW has also been deployed in 30% of UK NHS territories. MWDH have an emerging pipeline in Middle East, India and the USA, and is at the forefront of diabetes machine learning work. Debbie is also a Clinical Reader at University of Edinburgh and Diabetes Consultant, (MBChB, BSc, PhD, Clin Ed Dip), a Diabetes UK Clinical Champion, a 2017/18 NHS Innovation Accelerator Fellow and one of nine 2019 IUK Women in Innovation Award winners. She leads national programmes on diabetes artificial intelligence/ international diabetes education programmes. Previously, she was a health columnist for a national UK newspaper and TV doctor/presenter for STVs 'The Hour' programme.

“  
**She leads national programmes on diabetes artificial intelligence [...]**



**Jonathan Cameron, Deputy Director for Digital Health & Care, Scottish Government**

Jonathan is the Head of Digital Health and Care in Scottish Government, and is currently leading on digital Covid-19 response programmes including the Protect Scotland app and Covid Vaccinations. Jonathan has overall responsibility for the Digital Health and Care Strategy and has a key focus on ensuring the delivery of the new systems that are needed to support this in Scotland.

Prior to joining Scottish Government in November 2019,

Jonathan held a number of NHS Scotland IT and data posts, and has delivered several complex eHealth and Digital project and programmes, including the Key Information Summary (KIS) system.

Jonathan has been a CivTech challenge sponsor for the first 3 years of the programme and innovation has been a major focus throughout his career.

# Delivering service excellence

- \* GMP Sterile Manufacturing
- \* FDA and MHRA Inspected Facility
- \* Injectable Product Development
- \* Analytical Testing
- \* Biological Therapeutics and Vaccines
- \* Clinical Labelling & Packaging



# Session 3: The Pharmaceutical Supply Chain

11:20 - 12:00



## Dave Tudor, Managing Director MMIC, Biologics and Quality, CPI

Dave is the Managing Director of the Medicines Manufacturing Innovation Centre, Quality and Biologics. The Medicines Manufacturing Innovation Centre is a collaboration between CPI, University of Strathclyde, UK Research & Industry, Scottish Enterprise and founding industry partners, AstraZeneca and GSK.

The centre will ensure the UK is a technology and innovation leader in pharmaceutical manufacturing, thereby boosting the competitiveness of both sectors. The initial focus will be on



## Dr Julie Brady, Business Development Manager for Drug Discovery, University of Dundee

technology translation for small molecule drug manufacture.

Dave also leads the Biologics business unit, CPI's Quality function, which includes GMP obligations, and CPI's PMO function.

Prior to joining CPI in January 2019 Dave worked for GSK. He joined the company in 1992 as a PhD Chemist from Glasgow University. He has over 20 years' experience at GSK carrying out a number of Technical, Compliance and Manufacturing leadership roles. In 1997 he moved to Irvine to take up a lead chemist role before coming Quality Control Manager in 1998. He joined the site leadership team in 2001 to run Technical Development before moving to manufacturing as Actives Production Director in 2005.

During this time he completed a Masters degree in Manufacturing Leadership at Cambridge

Julie is Business Development Manager for Drug Discovery and sits in the Senior Leadership Team of the Drug Discovery Unit (DDU) at the University of Dundee. The DDU's aim is to translate basic science into lead compounds to validate putative drug targets, to use as tools to investigate disease pathways and, when appropriate, advance to pre-clinical drug candidates. A proficient business development leader with more than 20 years commercialisation and company growth experience, Julie leads the development of strategic collaboration and partnering in the DDU and has delivered commercial deals valued in excess of £50M.

University. In 2007 he moved to GSK House to work on a central network re-structuring project before becoming Site Director at Montrose in October 2008. At Montrose, he led the transformation of the site to manufacture over 12 products for GSK including a major investment programme. In 2011 he was appointed VP Primary Supply Chain with responsibility for global Active Pharmaceutical Ingredients (API) manufacture and supply, a network of GMS sites across the world including facilities in Asia and Europe. In 2017 he was appointed VP Head of GMS Strategy with responsibility for manufacturing strategy, deployment of strategic programmes, performance management and advocacy.

He plays an active role with a number of Governments and is currently co-chair of the Life Sciences Scotland Industry Leadership Group

Prior to this Julie spent 10 years as Life Sciences Manager for Scottish Enterprise managing a portfolio of high growth life sciences companies in Scotland and working with commercialisation opportunities emerging from the academic base. She managed the GSK Scotland Account working alongside Scottish Government colleagues to support strategic growth in GSK's manufacture sites.

Julie's research career began at the Rowett Research Institute in Aberdeen with a PhD in nutritional biochemistry followed by postdoctoral research in the University of Glasgow and the Rowett Research Institute.

# Session 3: The Pharmaceutical Supply Chain

11:20 - 12:00



**Tom Shepherd, Ph.D.,  
Chief Executive Officer,  
Captor Therapeutics**

Tom Shepherd is a native of Glasgow where he obtained his Ph.D. in biochemistry from the University of Strathclyde. He has spent the last 35 years in leadership positions in the pharma and biotech industry in the UK, USA, Australia, France, Switzerland, and Poland, with companies such as Kymab, Bausch Health, IntraBiotics, Auspharm and Novartis.

Tom is CEO and President of the Management Board of

Captor Therapeutics S.A. a drug discovery company based in Wroclaw, Poland, which recently completed the first IPO of a targeted protein degradation company in Europe.

Between 2002 and 2010, as CEO of CXR Biosciences in Dundee, Tom was frequently involved in the BioDundee conference and it is with great pleasure that he renews his participation in the conference for its 20th anniversary.



**Colin MacKay, CEO,  
Symbiosis Pharmaceutical Services**

As Founder and CEO of Symbiosis, Colin is responsible for driving the company's performance, creating maximum value for its shareholders, and actively promoting the successful development of long-term client relationships. He is responsible for business strategy development and all aspects of the company's day-to-day operations.

With 25 years of experience in the life science industry, from applied research to working for small and large organisations on an international basis, Colin has spent most of his career helping clients to successfully overcome their drug development challenges, mostly in the field of

“

**Colin has spent most of his career helping clients successfully overcome their drug development challenges [...]**

sterile contract pharmaceutical manufacturing.

Leading the senior management team, Colin ensures the company maintains its client-orientated philosophy and is always mindful of the fundamental importance of quality and compliance. He oversees the delivery of a service level that is instrumental in building mutually beneficial relationships with all stakeholders.

He holds a BSc (Hons) degree in Cell Biology and an MSc in Molecular Genetics from Glasgow University, and an MBA from Strathclyde University specialising in international marketing and strategic relationships.



# Session 3: The Pharmaceutical Supply Chain

11:20 - 12:00



**John Arthur, Director, Medicines Manufacturing Innovation Centre, CPI**

John is the Director of the Medicines Manufacturing Innovation Centre, Glasgow, a collaboration between CPI, University of Strathclyde, UK Research & Industry, Scottish Enterprise and founding industry partners, AstraZeneca and GSK.

The centre will ensure the UK is a technology and innovation leader in pharmaceutical manufacturing, thereby boosting the competitiveness of both sectors. The initial focus will be on technology translation for small molecule drug manufacture.

Prior to joining CPI in October 2019 John worked for GSK, joining the company in 1986 as a Process Chemist at the Worthing Site. During his time on Site he held roles covering all aspects of the manufacturing supply chain from large scale fermentation, fine chemicals (both chemical and enzymatic conversions), Chemical Development and Secondary Sterile Operations.

“

**During his time on Site he held roles covering all aspects of the manufacturing supply chain [...]**

After 10 years of site base roles he was seconded to Head office to lead a workstream of a global supply restructuring programme. In 2000 he moved to the Irvine plant to lead the Development team and take charge of the construction a new 300te nanomilling and spray drying plant. This period was followed with a number of roles working out of GSK House in strategic program leadership including Head of the Global Manufacturing & Supply Programme Management Office, 5 years in the Core Business Services Function (IT, Procurement and Real estate) as Head of PMO and finally back to manufacturing to Leader a Global manufacturing restructuring programme.

John has a BSc (Hons) in Chemistry, an MBA from Strathclyde University Business School, a Private Pilot's license and double decker bus license.



---

# Exhibitors 2021

---



# Session 4: Animal Health, Agri-Tech and Aqua Culture (AAA): Strengths and Opportunities in Scotland

13:00 - 13:40



## John MacKenzie, CEO, Roslin Innovation Centre (Chair)

In November 2014 John was appointed CEO of the Roslin Innovation Centre at the University of Edinburgh's Easter Bush Campus.

John started his career as a trainee accountant with Ernst and Young, followed by various accountancy posts in the voluntary, public and private sectors.

Prior to joining the University of Edinburgh, John worked for 14 years as the Head of Knowledge Exchange at Research and Innovation Services, the technology transfer office at the University of Dundee.

Previously, John worked in the Business Gateway in Dundee, where he provided business advice and mentoring to a diverse range of over 200 start-up and established businesses over a 4-year period.

As a highly experienced technology transfer and business incubator professional, John has provided advice, guidance and support to over 30 spinout and start-up ventures emanating from University staff and students.

John has also served as observer to the board on several of these spinout companies and he also managed the Dundee University Incubator where fledgling

technology businesses located within a community of technology entrepreneurs.

As mentor to many young entrepreneurs, and /or technology start-up companies, John sees their personal and business growth and success, as a measure of his own success.

Throughout his 20 year university-specific career, John has specialised in, and is passionate about, knowledge exchange, having actively encouraged and facilitated numerous knowledge transfer and innovation 'projects' between business and academia.

By applying all of his expertise and experience, John is now enjoying developing a dynamic place with 'buzz' that will bring together all the clinical, teaching, research, commercial and enterprise activities within one vibrant space, under the one Roslin Innovation Centre roof.



## Dr Simon Doherty, GlobalScot, Institute of Global Food Security, Queen's University Belfast

Simon holds a senior position at the Institute of Global Food Security, Queen's University Belfast where he works in the sphere of animal health and welfare, agricultural technology,

One Health and sustainability.

Prior to his presidency of the British Veterinary Association (2018-19), he was the Animal Sciences & Aquaculture Sector Specialist for the Department for International Trade and was appointed as a GlobalScot by the Office of the First Minister of Scotland in 2018. He currently sits on the 'Triple A' subgroup of the Life Sciences Scotland Industry Leadership Group.

He is a Director of Vet Sustain, a community interest company focussed on providing veterinary surgeons with resources and toolkits to drive sustainability in their workplaces and help their clients to improve their sustainability too. He has contributed to the work of international development organisation, Send a Cow, as a trustee, ambassador and veterinary advisor.

He has two decades of experience in veterinary practice, industry and academia, is a Certified Aquaculture Veterinarian, a Fellow of the Royal College of Veterinary Surgeons, a Fellow of the Royal Society of Biology, a Fellow of the Higher Education Academy and an Associate of the Royal Agricultural Societies.

A former Chair of the UK One Health Coordination Group, Simon currently chairs the Federation of Veterinarians of Europe Food Safety & Sustainability Working Group and was recently appointed as an ad hoc expert to the World Veterinary Association One Health Strategic Focus Group. He is a past-president of the North of Ireland Veterinary Association and a Life Member of the Royal Ulster Agricultural Society.

# Session 4: Animal Health, Agri-Tech and Aqua Culture (AAA): Strengths and Opportunities in Scotland

13:00 - 13:40



**Dr Lawrence Brown**  
**BVM&S MBA MRCVS,**  
**Innovation Manager**  
**for Health, Edinburgh**  
**Innovations**

Dr Lawrence John Brown BVM&S MBA MRCVS, a qualified veterinary surgeon and commercial consultant with international experience of clinical practice and the wider animal health sector. He is a member of the British Veterinary Association's (BVA) Scottish Council, KTN's Animal Sciences Advisory Board and Life Sciences Scotland's AAA (Animal Health, Agri-tech & Aquaculture) Industry Leadership Group. He co-founded 'A3 Scotland', Scotland's premier event for Agri-tech, Animal Health and Aquaculture, supported by the University of Edinburgh. Lawrence is also a mentor for start-ups at GROW, Southeast Asia's largest Agri-food tech accelerator, and EdVenture, the first pan-European university venture builder. Lawrence is motivated by the need for innovation and investment in order to advance animal health and sustainable food production.



**Dr. Jenna Bowen,**  
**Postdoctoral Researcher,**  
**SRUC / SEFARI Fellow**

Jenna is a postdoctoral researcher at SRUC's Beef and Sheep Research Centre. Her main interests are the use of agritech in ruminant production systems to improve efficiency and health. Jenna is also working on a SEFARI (Scottish Environment, Food and Agriculture Research

“

**Her main interests are the use of agritech in ruminant production systems to improve efficiency and health.**

Institutes) funded fellowship which aims to map out the current animal health, agritech and aquaculture (AAA) landscape in Scotland to help improve the understanding of sectoral strengths and opportunities. This fellowship is in collaboration with Highlands and Islands Enterprise and Life Science Scotland's Industry Leadership Group (AAA subgroup).



**David Farquhar, CEO, IGS Limited**

David joined IGS as CEO in November 2017. David's strategic appointment has successfully delivered a Series A funding round and seen the recruitment of a world-class management team. He now leads the company forward to drive global expansion.

David is a seasoned technology entrepreneur, with a track

record of driving shareholder value, based upon building an empowering, collaborative Culture as a Platform for growth. Most recently he was CEO of global SaaS vendor Workplace, leading the team through a hugely successful turnaround, transformation, growth and exit delivering a double-digit money multiple return in less than 3 years. In the past 27 years he has completed almost 30 transactions as a founder/CEO, angel investor and board director, including risk capital investments (PE, VC and angel), acquisitions and trade sales in Europe, North America and Asia.

# Session 5: 20 Years On: Reflecting and Looking to the Future

14:00 - 14:40

**SPONSORED BY:**  Research and  
Innovation Services  
University of Dundee



## **Alison Henderson, Chief Executive Officer, Dundee and Angus Chamber of Commerce (Chair)**

Alison is proud to have led the team at the Chamber since 1st November 2014 she is passionate about business and the local community, and is honoured to be Interim Chair of the Dundee & Angus Developing the Young Workforce Group. This employer-led group, created in response to the Wood Commission for Developing Scotland's Young Workforce, plays a vital role in the co-ordination and strengthening of engagement of employers in the agenda, to enable our region's young people to move into sustainable employment.

She is also Trustee of the George R Donald Fund, the Chamber's youth enterprise charity which began in 1965. The charity trustees, its members and the chamber team work to implement our benefactor's vision and to achieve the objectives of encouraging young people into enterprise & business.

Alison is also Past President of the Association of Scottish Businesswomen, who work with partners to support Scottish

Government on their Women in Enterprise Framework Agenda and Action Plan, and champion their network of over 700 women across Scottish businesses.

Alison is Co-Chair of the Dundee Work and Enterprise Group, sits on the Dundee Partnership Management Group, the Executive Group of the Angus Community Planning Partnership and is a member of the Dundee School of Business Advisory Board. She was a member of the first Fairness Commission in Dundee and believes passionately in equality and fairness for all.



## **Mary Ballantyne, Independent Consultant/ Current Team Leader, Covid-19 Immunisation Programme, NHS Tayside**

Mary has over 40 years experience spanning entrepreneurial projects, nursing, academia, pharmaceutical industry, life sciences and business.

Mary has seen many new ideas come through, medical developments, changes in nursing practice, and engagement with academia, blockbuster instruments developed to support

new medical techniques, drugs developed trialed licensed and brought to market-then withdrawn! Other drugs have gone on to world famous 1sts and much more!!

As for businesses she has been acquired, acquisitive and part of a multimillion sale never mind experienced expansion, retraction, boom and bust.

Some of Mary's work is exhibited in Dundee Science Centre Medical Marvels.

She is an experienced Agitator with Dundee University Centre of Entrepreneurship. Elevator UK - business Accelerators. Her offering is, a rich experience which supports entrepreneurs and startups through to investment, mentoring, coaching very experienced business people, scientists and nursing colleagues.

Currently on a number of Boards and supporting established, acquisitive and startups businesses covering diverse offerings from science related Recruitment to Medical Instrument Development, Diagnostics and Businesses which support Attitude, Behaviour and Culture as well as being a Trustee of a large successful health and well-being charity.

Since March 2020 Mary has re-engaged with the NHS supporting the COVID-19 Immunisation Programme as a senior nurse. A unique opportunity to return to her first love of nursing, experience the management of a pandemic and support the introduction and use of novel vaccines.

# Session 5: 20 Years On: Reflecting and Looking to the Future

14:00 - 14:40

**SPONSORED BY:**  Research and  
Innovation Services  
University of Dundee



## **Robin Presswood, Executive Director of City Development, Dundee City Council**

Robin Presswood is Executive Director of City Development at Dundee City Council, with responsibility for Planning and Building Standards, Economic Development, Roads & Transportation, Property, Engineering and Sustainability.

Robin started his local government career with Tayside Regional Council, had various elected, voluntary and non-executive posts with Dundee District Council, NHS Tayside and Scottish Arts Council, as well as jobs with Angus Council before joining Fife in 2004, where he was Head of a service combining planning, economic development, tourism, employability, building standards, environmental health, and trading standards.

“

**Robin started his local government career with Tayside Regional Council.**



## **Professor Derek Stewart, Director of the Advanced Plant Growth Centre, The James Hutton Institute**

Derek Stewart is the Director of the Advanced Plant Growth Centre, a £27M Tay Cities Deal Region growth project at the James Hutton Institute that aims to deliver increased commercial, economic and environmental benefits to the agricultural, food and drink sectors in the UK and internationally by innovative use of precision-controlled environment technologies. As director Prof Stewart is responsible for setting the strategic science, translation and business agendas for the APGC. Derek has over 30 years' experience in crop production, raw material composition and its relation to product quality, functionality, bioactivity and utility and this is reflected in his ~200 refereed publications and an H-Index of 59. He holds the Chair of Plant and food Chemistry at Heriot Watt University. Across his career he has coordination and co-led large national, international and EU grants. Current interests centre on developing the science and establishing the limits of vertical farming in food and pharma.



## **Sir Mike Ferguson, Regius Professor of Life Sciences, University of Dundee**

Mike Ferguson obtained a PhD in Biochemistry (1982) at London University. He was a Postdoctoral Fellow at the Rockefeller University, New York, with George Cross FRS and at Oxford University with Raymond Dwek FRS. He took up a lectureship at The University of Dundee in 1988 and was promoted to a personal chair in Molecular Parasitology in 1994 and was appointed the first Regius Professor of Life Sciences in 2013.

He has published over 250 peer reviewed research papers and is known for solving the first structures of glycosylphosphatidylinositol (GPI) membrane anchors, which play important roles throughout eukaryotic biology.

His research takes a multidisciplinary approach to understanding the biochemistry of protozoan parasites that cause tropical diseases, particularly the trypanosomatids that cause human African Sleeping Sickness, Chagas' disease and

Continued →

# Session 5: 20 Years On: Reflecting and Looking to the Future

14:00 - 14:40

**SPONSORED BY:**  Research and  
Innovation Services  
University of Dundee

leishmaniasis. He believes in the fundamental importance of working across the Biology / Chemistry interface and is particularly interested in Translational Research. Together with his colleagues, he was instrumental in establishing the Drug Discovery Unit at the University of Dundee and he is a member of the Wellcome Centre for Anti-Infectives Research. He is also co-Director of the successful Dundee Proteomics Facility.

“

**He was instrumental in establishing the Drug Discovery Unit at the University of Dundee.**

Mike was Dean of Research for Life Sciences from 2007-2014 and continues to play a role in Research Strategy. He led the construction of the Discovery Centre for Translational and Interdisciplinary Research and is co-lead on the Growing the Tay Cities BioMedical Cluster component of the Tay Cities Deal. He is Deputy Chair of The Wellcome Trust and a member of the Board of Directors of the Medicines for Malaria Venture (MMV).

Mike is a fellow of the Royal Societies of London and Edinburgh and of the Academy of Medical Sciences and a member of EMBO. He was knighted in 2019 for services to science.



## Simon Hewitt, Principle, Dundee and Angus College

Born in Portadown, Northern Ireland, Simon was educated at Portadown College and left Northern Ireland in 2001 to attend the University of Abertay Dundee, where he obtained a BSc (Hons) in Business Computing. Following a number of IT related roles, Simon moved into lecturing at Dundee College in 2008, specialising in Computer Network Management and Cisco Administration.

In November 2010 Simon was promoted to the role of Curriculum Manager in Computing at Dundee College and has remained in Academic Management since, becoming Vice Principal Curriculum & Attainment in 2016 within the now merged Dundee & Angus College and more recently securing the role of Principal in August 2020.

“

**Simon is involved in a number of national groups and boards including Chairing the Energy Skills Partnership board [...]**

Simon is involved in a number of national groups and boards including Chairing the Energy Skills Partnership board and board membership roles within Dundee Science Centre, Workers' Educational Association (WEA) Scotland and Students Awards Agency for Scotland (SAAS). Simon is also a member of the SQA Advisory Council, Data Lab skills advisory board, SDS Digital Skills advisory board and ScotlandIS Digital Skills advisory board.

# Session 6: What do the next 20 years hold for the Life Sciences and Healthcare Sectors?

15:00 - 15:40

SPONSORED BY: Invest in **DUNDEE**



**George Crooks, OBE,**  
Chief Executive Office,  
Digital Health & Care  
Innovation Centre (Chair)

Professor George Crooks is currently the Chief Executive of the Digital Health and Care Institute, Scotland's national innovation centre for digital health and care. He leads an organisation that is tasked with delivering innovation in

digital health and care that will help Scotland's people to live longer, healthier lives, deliver sustainable health and care services for the future and create economic benefits for Scotland. DHI provides opportunities for Scotland's public sector, academia and industry to co-design digital solutions to some of the country's biggest health and care challenges working with patients, service users and their families.

He was previously the Medical Director for NHS 24 and Director of the Scottish Centre for Telehealth & Telecare. George was a General Medical Practitioner for 23 years in Aberdeen latterly combining that role as Director of Primary Care for Grampian. George is on the Board of the European Connected Health Alliance and

is past president of the European Health Telematics Association. He is a Board member of TEC Quality, a UK organisation leading the implementation of quality standards and practices across the assisted living sector in the UK. He is an assessor for the European Commission on programmes involving digital health and care provision and is a member of the WHO roster of experts for digital health. He has been an advisor to several European governments and organisations on digital health and care. He is an advisor to Innovate UK for its Industrial Grand Challenge programme for Health Ageing. He is also an adjunct Professor of Telehealth at the University of Southern Denmark.

He was awarded an OBE in the Queen's New Year Honours List 2011 for services to healthcare.



**Richard Hebdon, Interim Deputy Director – Health & Life Sciences, Innovate UK**

Richard Hebdon is currently Interim Deputy Director for Health & Life Sciences at Innovate UK. He leads a team comprising 21 colleagues working across healthcare, biosciences and agri-food. The current live Sector project portfolio comprises 341 projects with a total offered grant value of £161.3M, as well as innovation infrastructure

investments including the Medicines Discovery and Cell & Gene Therapy Catapults, the four Agri-Tech Centres and the National Biofilms Innovation Centre.

Prior to joining Innovate UK, Richard worked in technology transfer, R&D management and research and innovation roles in industry and the public sector. This included working in pharmaceutical and vaccine discovery and FMCG product innovation.

“

**The current live Sector project portfolio comprises 341 projects with a total offered grant value of £161.3M.**

# Session 6: What do the next 20 years hold for the Life Sciences and Healthcare Sectors?

15:00 - 15:40

SPONSORED BY: Invest in **DUNDEE**



**Calum MacRae MD, PhD.,**  
Director, One Brave Idea,  
Vice Chair for Scientific  
Innovation, Department  
of Medicine, Brigham  
and Women's Hospital,  
Professor, Harvard  
Medical School

Calum A. MacRae, MD, PhD, is the Director of One Brave Idea (an innovation program founded by Verily, the American Heart Association and AstraZeneca), Vice Chair for Scientific Innovation in the Department of Medicine at Brigham and Women's Hospital in Boston, a Professor of Medicine at Harvard Medical School, a

Principal Faculty Member at the Harvard Stem Cell Institute and an Associate Member at the Broad Institute of Harvard and MIT. He is also the Principal Investigator of the Apple Heart & Movement Study, a Co-Founder of Atman Health and an advisor to Foresite Labs and Clarify Health Solutions. He trained in medicine, genetics

“

**Dr. MacRae works on the genetic basis of human disease, moving genomics and novel large-scale datasets into clinical practice [...]**

and developmental biology in Edinburgh, London and Boston.

Dr. MacRae works on the genetic basis of human disease, moving genomics and novel large-scale datasets into clinical practice, systematic approaches to digital health, and the role of disruptive innovation in refashioning the translational interface.



**Dr. Alison Dun, Executive Director, Scottish Universities Life Sciences Alliance (SULSA)**

Alison Dun is the Executive Director for the Scottish Universities Life Science Alliance (SULSA), which drives strategic collaboration across Universities, disciplines and sectors. Within this role Alison drives SULSA's skills agenda, working in

partnership with national agencies and organisations to support the life science skills pipeline. Furthermore, Alison leads on multiple multi-organisation projects, working towards sustainable economic recovery, with research and innovation at their core.

After obtaining her degree in Molecular Medicine at the University of Sussex, Alison undertook her PhD at the University of Edinburgh, using advanced microscopy to investigate molecular mechanisms at the cellular membrane. After completing her PhD in 2013 Alison became the facility manager for the Edinburgh Super-Resolution Imaging Consortium (ESRIC) at Heriot-Watt University. Alison established ESRIC as a globally recognised centre of excellence

for advanced microscopy, providing access to state-of-the-art microscopy equipment and the expertise to support high impact research. Under Alison's leadership ESRIC won a TIMES Higher Education Award, hosted the Nobel Prize Winner for Physics and Chemistry 2014 and secured funding for the only microscope of its kind in Scotland (£1.2 million).

With a passion for driving collaboration and an interest in policy, Alison joined SULSA as Executive Director in March 2020. Since joining Alison has worked across the 10 Research Pools in Scotland to create Research Innovation Scotland and continues to build SULSA's activity in skills development and the improvement of research culture.

# Session 6: What do the next 20 years hold for the Life Sciences and Healthcare Sectors?

15:00 - 15:40

SPONSORED BY: Invest in **DUNDEE**



**Andrew Fowlie, Lead for Health, Social Care and Industrial Innovation, Scottish Government**

Andrew works for the Scottish Government's Chief Scientist's Office Innovation Team with a focus on bringing new health and social care innovations into the NHS and Social Care. Supporting the Government's Innovation Plan to increase the quality and quantity of industrial innovation in health care and Life Sciences. Specifically driving productivity in public and private sectors to sustain health care services and harness global innovations.

Levering exponential change in mobile computing, digital manufacturing, robotics, artificial intelligence, networks & sensors and systems biology. Supporting convergence of activity in these areas through proactive

collaboration between industry, academia and the NHS. Engaging with international experts to resolve known local challenges and find future solutions through creative collaborations.

Andrew has a strong association with Life Sciences and economic development in Scotland aligning closely with European and Global interests. National role in bringing exponentially changing health innovations into the Scottish market.

He has 30 years in practice and Executive Management in health and social care with post graduate qualifications in Economics, Business Management and Primary Care.

## Closing Remarks

from Dr Johnathan Snape,  
Head of James Hutton Ltd

15:40



# THANK YOU

## to our event sponsors



AMICULUM® is an independent global health communications and consultancy business that works with pharmaceutical, biotechnology and health technology companies across the world. Our specialist services include medical communications, healthcare learning, creative design, clinical and commercial consultancy, support for market access and digital engagement. AMICULUM supports products in a wide range of therapy areas and has teams that focus specifically on rare diseases and advances in genomic medicine.

Created in 2001, AMICULUM has grown steadily for the past 20 years and now employs over 300 people worldwide. We have teams based across multiple locations in New Zealand, China, Hong Kong, Singapore, UAE, Switzerland, UK and USA. We have a team based on the campus of the University of Dundee.

## Medtronic

Making healthcare better is our priority, and we believe medical technology can play an even greater role in improving people's lives. With challenges facing families and healthcare systems — such as rising costs, aging populations, and the burden of chronic disease — we are using the power of technology to take healthcare Further, Together. Innovation and collaboration are central to who we are. Since the late 1940s, we have been working with others to alleviate pain, restore health, and extend life. Today, we are a medical technology leader, employing more than 84,000 people worldwide, and offering therapies and solutions that enable greater efficiency, access, and value — for healthcare systems, providers, and the people they serve.



SCOTTISH HEALTH INNOVATIONS

## Proud sponsors of the 20th BioDundee Conference

Scottish Health Innovations Ltd (SHIL) works in partnership with NHS Scotland to identify, protect, develop and commercialise impactful healthcare innovations that make a positive difference to health, social and economic outcomes.




Read our new strategy  
**Innovating Together** at  
[www.shil.co.uk/strategy](http://www.shil.co.uk/strategy)



# School of Life Sciences University of Dundee

The facilities within our Centre for Advanced Scientific Technologies and our Data Analysis Group offer a number of services to support state-of-the-art biomedical and biological sciences research. Click on a facility for more information and find out how we can support your needs.



Henderson Loggie has been serving Scotland and Scottish business for well over a century. Our vision is to be first choice in Scotland as a place to work and for our services to our clients.

Our purpose is to help our teams and our clients achieve their potential, to create wealth for the local economy now and to leave legacy for the future in the communities where we are located.

We have a specialist Lifescience sector team and have been involved with Bio-Dundee since its inception, we are proud to be sponsors of this year's event.



Scottish Health Innovations Ltd (SHIL) works in partnership with NHS Scotland to identify, protect, develop and commercialise forward-thinking, impactful healthcare innovations that positively impact health, social and economic outcomes in Scotland.

Drawing on almost 20 years of operational experience, SHIL's multidisciplinary team utilises specialised knowledge to help bring new ideas and innovations from healthcare professionals to life. Expert services including intellectual property advice and protection, regulatory expertise, project management, idea incubation, funding advice, development and commercialisation, and post-commercialisation monitoring.

SHIL believes ground breaking ideas have the power to significantly improve health and social care for all, while supporting an ambitious, entrepreneurial, forward-thinking Scotland. Working collaboratively with the NHS, academia, industry, entrepreneurs and funders we are committed to accelerating innovation and entrepreneurship across all areas of health.



---

# THANK YOU

## to our event sponsors

---



Research and  
Innovation Services  
University of Dundee


Bridging academia and industry, we are key strategic drivers of innovation and commercialisation, offering opportunities to develop and grow your business through access to academic knowledge and resources.



Invest in Dundee is an inward investor service delivered by Dundee City Council in partnership with local and national agencies. It aims to promote Dundee as a world class location for investment and to provide potential investors with information and support. With a regenerated waterfront, an international class design museum in V&A Dundee, a spectacular river setting, 2 industry focused universities, a commitment to green recovery and an affordable cost base, there has never been a better time to consider Dundee.



The School of Life Sciences at the University of Dundee offers several technologies and resources to support state-of-the-art biomedical and biological sciences research. The facilities in our Centre for Advanced Scientific Technologies and our Data Analysis Group are also integral to our interdisciplinary and collaborative research ethos.



Symbiosis is a world class manufacturer specialising in cGMP sterile fill/finish of biopharmaceuticals for clinical trials and niche commercial markets including viral vector Advanced Therapeutics Medicinal Products (ATMPs). The competitive strengths of Symbiosis include MHRA and FDA-inspected standard regulatory compliance, expert technical capabilities and exceptional operational flexibility.

Incorporated in 2011, Symbiosis has specialist capabilities to support biotechnology and pharmaceutical clients who are developing either biologic or small molecule injectable drug products. One of the company's key strengths is in accelerating the release of drug product which provides significant value by ensuring clients tight timelines are successfully met.

Manufacturing takes place in a first-class manufacturing facility, enabling Symbiosis to manufacture a broad range of liquid or lyophilized drug products including viral vectors, antibodies, proteins, peptides and small molecules in addition to the ability to handle cytotoxic anti-cancer drugs and antibody-drug conjugates.

---

# THANK YOU

## to our event sponsors

---



Cellexus research, develop and manufacture the CellMaker range of revolutionary single-use, airlift bioreactor systems and related technology.

The most innovative airlift technology on the market, the CellMaker system offers a reduced investment alternative to existing technologies with a combined low footprint and excellent performance. The CellMaker bioreactors are available in 8L and 50L and the option of fitted sensors for pH and dissolved oxygen to enhance process control, maximise yields and reduce time to market. The CellMaker range is designed to be versatile and has been proven in a wide range of cell lines (E Coli, Pichia, Bacteriophage, Yeast, Algae) for fermentation applications used in the life sciences and biopharmaceutical industries. We enable our customers to accelerate their processes and increase their yields when compared to standard methods.



Johnston Carmichael is the largest firm of accountants and business advisers in Scotland and the go to firm for ambitious entrepreneurial companies. With 13 offices, including Dundee, and over 750 staff and partners, they also have global reach via their membership of PKF International, a network of independent member firms with over 400 offices in 150 countries.

Technology and life sciences are amongst their core sectors and the JC team use their expertise to act as trusted advisers to their clients, offering deep industry knowledge and astute technical insight across audit, tax, personal finance and other key areas.

